Enzom-DR Tablet is a combination pharmaceutical formulation containing Trypsin (48 mg), Bromelain (90 mg), Rutoside (100 mg), and Diclofenac (50 mg), designed for the management of inflammatory conditions and associated pain. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, thereby reducing edema and promoting the resolution of inflammation. Rutoside, a bioflavonoid, exerts antioxidant properties and strengthens capillary walls, contributing to decreased vascular permeability and enhanced microcirculation. Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), provides potent analgesic and anti-inflammatory effects by inhibiting cyclooxygenase enzymes, thereby reducing prostaglandin synthesis. The synergistic action of these components makes Enzom-DR effective in alleviating symptoms of acute and chronic inflammatory disorders such as musculoskeletal injuries, postoperative swelling, and soft tissue trauma. It is typically prescribed to reduce pain, swelling, and inflammation, improving patient mobility and comfort. Enzom-DR should be used under medical supervision, considering contraindications such as hypersensitivity to NSAIDs, gastrointestinal ulcers, or bleeding disorders. Monitoring for adverse effects, including gastrointestinal discomfort or allergic reactions, is advised during therapy. This combination offers a comprehensive approach to inflammation management by targeting multiple pathophysiological pathways.